An Open-Label, Prospective, Non-Comparative Study to Evaluate the Efficacy and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia.
Phase of Trial: Phase IV
Latest Information Update: 06 Jan 2015
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms PREVAIL
- Sponsors Johnson & Johnson
- 13 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record
- 06 Nov 2013 Planned end date changed from 1 Apr 2014 to 1 Jan 2014 as reported by ClinicalTrials.gov.